Mayinglong Pharmaceutical Group Co Ltd - Asset Resilience Ratio
Mayinglong Pharmaceutical Group Co Ltd (600993) has an Asset Resilience Ratio of 20.74% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 600993 liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2001–2024)
This chart shows how Mayinglong Pharmaceutical Group Co Ltd's Asset Resilience Ratio has changed over time. See Mayinglong Pharmaceutical Group Co Ltd net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Mayinglong Pharmaceutical Group Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Mayinglong Pharmaceutical Group Co Ltd market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.11 Billion | 20.74% |
| Total Liquid Assets | CN¥1.11 Billion | 20.74% |
Asset Resilience Insights
- Good Liquidity Position: Mayinglong Pharmaceutical Group Co Ltd maintains a healthy 20.74% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Mayinglong Pharmaceutical Group Co Ltd Industry Peers by Asset Resilience Ratio
Compare Mayinglong Pharmaceutical Group Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC |
Drug Manufacturers - Specialty & Generic | 43.05% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Henan Newland Pharmaceutical Co. Ltd. A
SHE:301277 |
Drug Manufacturers - Specialty & Generic | 31.63% |
|
Hainan Shuangcheng Pharmaceut
SHE:002693 |
Drug Manufacturers - Specialty & Generic | 3.29% |
Annual Asset Resilience Ratio for Mayinglong Pharmaceutical Group Co Ltd (2001–2024)
The table below shows the annual Asset Resilience Ratio data for Mayinglong Pharmaceutical Group Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 2.74% | CN¥142.14 Million ≈ $20.80 Million |
CN¥5.18 Billion ≈ $758.28 Million |
+1.43pp |
| 2023-12-31 | 1.31% | CN¥63.29 Million ≈ $9.26 Million |
CN¥4.83 Billion ≈ $706.71 Million |
-12.02pp |
| 2022-12-31 | 13.33% | CN¥674.35 Million ≈ $98.68 Million |
CN¥5.06 Billion ≈ $740.09 Million |
+10.76pp |
| 2021-12-31 | 2.57% | CN¥106.02 Million ≈ $15.51 Million |
CN¥4.13 Billion ≈ $603.90 Million |
+1.63pp |
| 2020-12-31 | 0.94% | CN¥36.32 Million ≈ $5.31 Million |
CN¥3.87 Billion ≈ $565.78 Million |
-1.93pp |
| 2019-12-31 | 2.87% | CN¥94.32 Million ≈ $13.80 Million |
CN¥3.29 Billion ≈ $480.76 Million |
+0.11pp |
| 2018-12-31 | 2.77% | CN¥80.93 Million ≈ $11.84 Million |
CN¥2.93 Billion ≈ $428.24 Million |
-4.79pp |
| 2017-12-31 | 7.55% | CN¥208.00 Million ≈ $30.44 Million |
CN¥2.75 Billion ≈ $402.99 Million |
+6.71pp |
| 2016-12-31 | 0.85% | CN¥21.17 Million ≈ $3.10 Million |
CN¥2.50 Billion ≈ $365.35 Million |
-0.35pp |
| 2015-12-31 | 1.20% | CN¥28.81 Million ≈ $4.22 Million |
CN¥2.41 Billion ≈ $352.64 Million |
-1.19pp |
| 2014-12-31 | 2.38% | CN¥52.05 Million ≈ $7.62 Million |
CN¥2.19 Billion ≈ $319.83 Million |
+0.41pp |
| 2013-12-31 | 1.97% | CN¥39.98 Million ≈ $5.85 Million |
CN¥2.03 Billion ≈ $296.68 Million |
-0.06pp |
| 2012-12-31 | 2.03% | CN¥37.37 Million ≈ $5.47 Million |
CN¥1.84 Billion ≈ $269.67 Million |
-3.47pp |
| 2011-12-31 | 5.49% | CN¥91.07 Million ≈ $13.33 Million |
CN¥1.66 Billion ≈ $242.56 Million |
+1.34pp |
| 2010-12-31 | 4.15% | CN¥60.12 Million ≈ $8.80 Million |
CN¥1.45 Billion ≈ $212.02 Million |
+1.42pp |
| 2009-12-31 | 2.73% | CN¥39.15 Million ≈ $5.73 Million |
CN¥1.44 Billion ≈ $210.11 Million |
-10.32pp |
| 2008-12-31 | 13.05% | CN¥151.74 Million ≈ $22.20 Million |
CN¥1.16 Billion ≈ $170.17 Million |
+9.31pp |
| 2007-12-31 | 3.74% | CN¥40.84 Million ≈ $5.98 Million |
CN¥1.09 Billion ≈ $159.74 Million |
+3.61pp |
| 2006-12-31 | 0.13% | CN¥1.45 Million ≈ $211.62K |
CN¥1.11 Billion ≈ $161.80 Million |
+0.12pp |
| 2003-12-31 | 0.01% | CN¥50.59K ≈ $7.40K |
CN¥367.95 Million ≈ $53.84 Million |
-0.15pp |
| 2002-12-31 | 0.16% | CN¥580.07K ≈ $84.88K |
CN¥363.13 Million ≈ $53.14 Million |
+0.11pp |
| 2001-12-31 | 0.05% | CN¥151.42K ≈ $22.16K |
CN¥320.89 Million ≈ $46.96 Million |
-- |
About Mayinglong Pharmaceutical Group Co Ltd
Mayinglong Pharmaceutical Group Co., Ltd., together with its subsidiaries, manufactures and sells Chinese and Western medicines in China and internationally. The company offers functional cosmetics, functional care products and food, Chinese herbal medicines, and medical devices. It also manufactures, processes, and sells medicinal packaging materials, cosmetics, and Chinese medicines; and offers… Read more